Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability
Abstract Lung cancer remains the leading cause of cancer-related deaths in Europe, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases. NSCLC is a heterogeneous disease encompassing various oncogenic alterations. Among them, EGFR exon 20 insertion mutations, constitutin...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-01-01
|
| Series: | BMC Proceedings |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12919-023-00287-6 |
| _version_ | 1797350100433895424 |
|---|---|
| author | Maximilian J. Hochmair Mojca Unk Jelena Spasic Timur Cerić Assia Konsoulova Mircea Dediu Krisztina Bogos Alinta Hegmane Kersti Oselin Marko Stojiljkovic Tina Roblek Marko Jakopovic |
| author_facet | Maximilian J. Hochmair Mojca Unk Jelena Spasic Timur Cerić Assia Konsoulova Mircea Dediu Krisztina Bogos Alinta Hegmane Kersti Oselin Marko Stojiljkovic Tina Roblek Marko Jakopovic |
| author_sort | Maximilian J. Hochmair |
| collection | DOAJ |
| description | Abstract Lung cancer remains the leading cause of cancer-related deaths in Europe, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases. NSCLC is a heterogeneous disease encompassing various oncogenic alterations. Among them, EGFR exon 20 insertion mutations, constituting 0.3–2.2% of NSCLC cases, rank as the third most common EGFR alteration after exon 19 deletions and the L858R point mutation in exon 21, also known as “typical” EGFR alterations. Recent advancements in understanding the molecular pathogenesis of NSCLC have led to significant breakthroughs in targeted therapies, revolutionizing treatment options for patients with specific genetic alterations. This article presents the outcomes of a Virtual Meeting conducted on the online platform (provided Within3©) from September 19 to October 30, 2022. The meeting focused on addressing the challenges in the diagnosis and treatment of NSCLC patients with EGFR exon 20 insertion mutations. The participants consisted of healthcare professionals from ten Central and Eastern European countries who shared their experiences and opinions on various aspects, including epidemiology, treatment options, and diagnostic approaches employed in their respective healthcare institutions. The discussions were facilitated through open-ended and multiple-choice questions. The primary objective of this article is to provide an overview of the identified challenges associated with the diagnosis and treatment of this heterogeneous disease, based on the assessments of the meeting participants. Among the major emerging challenges discussed, the reimbursement issues concerning next-generation sequencing (NGS), a recommended method in NSCLC molecular diagnosis, and the availability of approved targeted treatments to enhance patient outcomes were of paramount importance. Furthermore, fostering community awareness of lung cancer and promoting harmonized lung cancer care were identified as areas deserving greater attention. Notably, the rapidly evolving treatment landscape, particularly with NGS for NSCLC patients with genomic alterations like EGFR, ALK, RET, MET, NTRK, and ROS1, necessitates prioritizing the development of new drugs, even for the relatively smaller subgroup with exon 20 insertion mutations. |
| first_indexed | 2024-03-08T12:40:55Z |
| format | Article |
| id | doaj.art-f9f7e046c374460e862662228b2b71f4 |
| institution | Directory Open Access Journal |
| issn | 1753-6561 |
| language | English |
| last_indexed | 2024-03-08T12:40:55Z |
| publishDate | 2024-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Proceedings |
| spelling | doaj.art-f9f7e046c374460e862662228b2b71f42024-01-21T12:12:37ZengBMCBMC Proceedings1753-65612024-01-0118S31710.1186/s12919-023-00287-6Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availabilityMaximilian J. Hochmair0Mojca Unk1Jelena Spasic2Timur Cerić3Assia Konsoulova4Mircea Dediu5Krisztina Bogos6Alinta Hegmane7Kersti Oselin8Marko Stojiljkovic9Tina Roblek10Marko Jakopovic11Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik FloridsdorfInstitute of Oncology LjubljanaInstitute for Oncology and Radiology of SerbiaUniversity Clinical Center SarajevoNational Oncology HospitalSanador Oncology Center BucharestNational Koranyi Institute for PulmonologyRiga East University Hospital, Oncology Center of LatviaNorth Estonia Medical CentreTakeda d.o.o.Takeda Pharmaceuticals d.o.o.Zagreb Medical School, University Clinical Hospital Center ZagrebAbstract Lung cancer remains the leading cause of cancer-related deaths in Europe, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases. NSCLC is a heterogeneous disease encompassing various oncogenic alterations. Among them, EGFR exon 20 insertion mutations, constituting 0.3–2.2% of NSCLC cases, rank as the third most common EGFR alteration after exon 19 deletions and the L858R point mutation in exon 21, also known as “typical” EGFR alterations. Recent advancements in understanding the molecular pathogenesis of NSCLC have led to significant breakthroughs in targeted therapies, revolutionizing treatment options for patients with specific genetic alterations. This article presents the outcomes of a Virtual Meeting conducted on the online platform (provided Within3©) from September 19 to October 30, 2022. The meeting focused on addressing the challenges in the diagnosis and treatment of NSCLC patients with EGFR exon 20 insertion mutations. The participants consisted of healthcare professionals from ten Central and Eastern European countries who shared their experiences and opinions on various aspects, including epidemiology, treatment options, and diagnostic approaches employed in their respective healthcare institutions. The discussions were facilitated through open-ended and multiple-choice questions. The primary objective of this article is to provide an overview of the identified challenges associated with the diagnosis and treatment of this heterogeneous disease, based on the assessments of the meeting participants. Among the major emerging challenges discussed, the reimbursement issues concerning next-generation sequencing (NGS), a recommended method in NSCLC molecular diagnosis, and the availability of approved targeted treatments to enhance patient outcomes were of paramount importance. Furthermore, fostering community awareness of lung cancer and promoting harmonized lung cancer care were identified as areas deserving greater attention. Notably, the rapidly evolving treatment landscape, particularly with NGS for NSCLC patients with genomic alterations like EGFR, ALK, RET, MET, NTRK, and ROS1, necessitates prioritizing the development of new drugs, even for the relatively smaller subgroup with exon 20 insertion mutations.https://doi.org/10.1186/s12919-023-00287-6EGFR exon 20 insertion mutationsNSCLC treatmentDiagnostic challengesTargeted therapiesNext-generation sequencingHealthcare disparities in Central and Eastern Europe |
| spellingShingle | Maximilian J. Hochmair Mojca Unk Jelena Spasic Timur Cerić Assia Konsoulova Mircea Dediu Krisztina Bogos Alinta Hegmane Kersti Oselin Marko Stojiljkovic Tina Roblek Marko Jakopovic Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability BMC Proceedings EGFR exon 20 insertion mutations NSCLC treatment Diagnostic challenges Targeted therapies Next-generation sequencing Healthcare disparities in Central and Eastern Europe |
| title | Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability |
| title_full | Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability |
| title_fullStr | Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability |
| title_full_unstemmed | Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability |
| title_short | Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability |
| title_sort | unmet needs in egfr exon 20 insertion mutations in central and eastern europe reimbursement diagnostic procedures and treatment availability |
| topic | EGFR exon 20 insertion mutations NSCLC treatment Diagnostic challenges Targeted therapies Next-generation sequencing Healthcare disparities in Central and Eastern Europe |
| url | https://doi.org/10.1186/s12919-023-00287-6 |
| work_keys_str_mv | AT maximilianjhochmair unmetneedsinegfrexon20insertionmutationsincentralandeasterneuropereimbursementdiagnosticproceduresandtreatmentavailability AT mojcaunk unmetneedsinegfrexon20insertionmutationsincentralandeasterneuropereimbursementdiagnosticproceduresandtreatmentavailability AT jelenaspasic unmetneedsinegfrexon20insertionmutationsincentralandeasterneuropereimbursementdiagnosticproceduresandtreatmentavailability AT timurceric unmetneedsinegfrexon20insertionmutationsincentralandeasterneuropereimbursementdiagnosticproceduresandtreatmentavailability AT assiakonsoulova unmetneedsinegfrexon20insertionmutationsincentralandeasterneuropereimbursementdiagnosticproceduresandtreatmentavailability AT mirceadediu unmetneedsinegfrexon20insertionmutationsincentralandeasterneuropereimbursementdiagnosticproceduresandtreatmentavailability AT krisztinabogos unmetneedsinegfrexon20insertionmutationsincentralandeasterneuropereimbursementdiagnosticproceduresandtreatmentavailability AT alintahegmane unmetneedsinegfrexon20insertionmutationsincentralandeasterneuropereimbursementdiagnosticproceduresandtreatmentavailability AT kerstioselin unmetneedsinegfrexon20insertionmutationsincentralandeasterneuropereimbursementdiagnosticproceduresandtreatmentavailability AT markostojiljkovic unmetneedsinegfrexon20insertionmutationsincentralandeasterneuropereimbursementdiagnosticproceduresandtreatmentavailability AT tinaroblek unmetneedsinegfrexon20insertionmutationsincentralandeasterneuropereimbursementdiagnosticproceduresandtreatmentavailability AT markojakopovic unmetneedsinegfrexon20insertionmutationsincentralandeasterneuropereimbursementdiagnosticproceduresandtreatmentavailability |